Can a blood test monitor lymphoma?

Leukemia and Lymphoma

Volumn 51, Issue 6, 2010, Pages 957-959

  Jones, Kimberley ^a   Gandhi, Maher K ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; ANTINEOPLASTIC AGENT; ASPARAGINASE; DAUNORUBICIN; PREDNISONE; VINCRISTINE;

BLOOD ANALYSIS; CLASSICAL HODGKIN LYMPHOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; EPSTEIN BARR VIRUS; FUNDING; HUMAN; IN SITU HYBRIDIZATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; NK T CELL LYMPHOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; T LYMPHOCYTE; VIRUS LOAD; BLOOD; CHILD; EPSTEIN BARR VIRUS INFECTION; GENETICS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; OUTCOME ASSESSMENT; PHYSIOLOGIC MONITORING; POLYMERASE CHAIN REACTION; PROCEDURES; PROGNOSIS; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; DAUNORUBICIN; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MONITORING, PHYSIOLOGIC; OUTCOME ASSESSMENT (HEALTH CARE); POLYMERASE CHAIN REACTION; PREDNISONE; PROGNOSIS; VINCRISTINE;

EID: 77953487280     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.487623     Document Type: Note

References (15)

1. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Riskadapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896-1903.
2. Gandhi MK. Epstein-Barr virus-associated lymphomas. Expert Rev Anti Infect Ther 2006;4:77-89.
3. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999;18:65-73.
4. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966-3968.
5. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650.
6. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999; 84:442-448.
7. Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein- Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006;12:460-464.
8. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBVpositive lymphomas in immunocompetent patients. Blood 2004;104:243-249.
9. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-2470.
10. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein- Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000;96: 4055-4063.
11. Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003;63: 2028-2032.
12. Ryan JL, Fan H, Swinnen LJ, et al. Epstein-Barr virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 2004;13: 61-68.
13. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010;107:6328-6333.
14. Machado ASC, da Silva Robaina MC, Magalhães de Rezende LM, et al. Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas. Leuk Lymphoma 2010;51:1020-1027.
15. Gandhi MK, Wilkie GM, Dua U, et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007;7:1293-1299.